Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.

ABSTRACT: Emerging viral infections are difficult to control because heterogeneous members periodically cycle in and out of humans and zoonotic hosts, complicating the development of specific antiviral therapies and vaccines. Coronaviruses (CoVs) have a proclivity to spread rapidly into new host species causing severe disease. Severe acute respiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV) successively emerged, causing severe epidemic respiratory disease in immunologically naïve human populations throughout the globe. Broad-spectrum therapies capable of inhibiting CoV infections would address an immediate unmet medical need and could be invaluable in the treatment of emerging and endemic CoV infections. We show that a nucleotide prodrug, GS-5734, currently in cli

SUBMITTER: Sheahan TP 

PROVIDER: S-EPMC5567817 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature